Bay­er sells testos­terone treat­ment to Ger­man com­pa­ny for $500M

Bay­er AG is all set to sell its testos­terone de­fi­cien­cy treat­ment Nebido to Grü­nen­thal, a Ger­man pain man­age­ment com­pa­ny for about $500 mil­lion.

The deal is ex­pect­ed to close by end of 2022 and could add about $99 mil­lion to Grü­nen­thal’s EBID­TA by 2023.

“This di­vest­ment is part of the on­go­ing trans­for­ma­tion of our phar­ma­ceu­ti­cals busi­ness, which fo­cus­es on key ar­eas of health­care in­no­va­tion,” said Mar­i­anne De Backer, head of strat­e­gy and busi­ness de­vel­op­ment at Bay­er, in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER